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Abstract 23 
The tumor microenvironment (TME) is an attractive target to develop novel strategies for 24 
hormone-dependent cancers. Several molecules in the TME can favor tumor development 25 
and progression, including lipoproteins. Lipoproteins are taken up by cancer cells providing 26 
them with cholesterol and fatty acids. Cholesterol regulates cell signaling and it is converted 27 
into a series of bioactive metabolites, including hormones. The conflicting results of 28 
epidemiological and interventional studies suggest that the local availability of lipoproteins in 29 
the TME is more relevant for cancer biology than their circulating levels. Thus, reducing 30 
lipoprotein uptake and stimulating cell cholesterol efflux to high density lipoproteins (HDL) can 31 
represent a novel adjuvant strategy for cancer management. HDL-like particles can also act 32 
as drug delivery systems for tumor targeting.   33 
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Relevance of the microenvironment in tumor development and progression 34 
Hormones can drive the development and the progression of malignancies at multiple sites, 35 
including adrenal, thyroid, parathyroid, pancreatic, prostate and reproductive tissues. This 36 
review is mainly focused on breast and prostate cancers (BC and PCa), which are the leading 37 
cause of cancer-related death in women and men, respectively. They are classified as 38 
hormone-dependent cancers due to the key role of steroid sexual hormones in tumor initiation 39 
and progression (see Box 1). Both types of cancer are characterized by an effective response 40 
to hormone-deprivation therapies; however, therapeutic options for locally advanced or 41 
metastatic tumors are limited and poorly effective [1,2]. 42 
In the attempt to identify the mechanisms responsible for tumor progression and to find novel 43 
therapeutic targets, the tumor microenvironment (TME) has gained increased attention. The 44 
TME is as a complex, acidic and hypoxic environment, with cancer cells and non-transformed 45 
stromal cells of different origins immersed in the extracellular matrix (ECM), that evolves 46 
during tumor progression [3]. Cellular components include endothelial cells and pericytes, 47 
fibroblasts, adipocytes, resident and infiltrating immune cells, while the ECM, which provides 48 
a structural support for these surrounding cells, is mainly composed by collagen, elastin, 49 
fibronectin, laminin and proteoglycans (PGs). The role of the different stromal cells in tumor 50 
development and progression is complex and still debated, as recently reviewed by Hanahan 51 
and Mittal [4,5]. Interestingly, TME can modulate malignant progression in multiple ways and 52 
TME signature can predict disease outcome and therapeutic response, independent from 53 
cancer cell features, as in the case of BC [6,7]. 54 
Several molecules in the TME can favor the development and progression of hormone-55 
dependent cancers. It is well established the role of pro-oxidant and pro-inflammatory 56 
molecules, which can reach the TME from the systemic circulation or can be locally produced 57 
by stromal cells [8]. In addition, sources of cholesterol and fatty acids are present in the TME; 58 
these molecules can promote cancer cell proliferation through several mechanisms beyond 59 
their well-known structural and energetic role in cell physiology (see Box 2). 60 
Cholesterol and its metabolites in cancer cells 61 
The role of cholesterol in the context of cancer cell proliferation has been recently revised. In 62 
the past, cholesterol need was ascribed to its structural role in cell membranes, while now it is 63 
recognized as a key player in the regulation of cellular function (Figure 1). Its presence in cell 64 
membranes is able to modulate the activation of transmembrane receptors [9]. In addition, it 65 
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can be converted into a wide series of biologically active metabolites, such as oxysterols and 66 
isoprenoids [10]. Finally, cholesterol acts as a building block for the local synthesis of 67 
hormones. Consequently, cholesterol demand is higher in hormone-dependent cancers 68 
compared to other tumor types [11]. 69 
Cholesterol can be directly synthetized by cancer cells or it can be taken up by lipoproteins 70 
(see box 3 and box 4), which are present in extracellular fluids (Figure 1). Indeed, the 71 
receptor-mediated endocytosis of apoB-containing lipoproteins and, depending on the 72 
cholesterol gradient, the SR-BI-facilitated cholesterol influx from HDL, are relevant sources of 73 
cholesterol in the TME [12]. On the contrary, HDL could help in reducing cholesterol content 74 
of cancer cells acting as acceptors of cholesterol efflux [13]. To deal with their need of 75 
cholesterol, cancer cells are generally characterized by an increased expression of SREBP-76 
regulated genes, which support cholesterol synthesis and uptake, and by a concomitant 77 
inhibition of LXR-regulated genes, including ABC transporters [14,15] (Figure 2). Cancer cell 78 
uptake of lipoproteins in the TME is promoted by hypoxia; indeed, in several cancer cell 79 
lines, hypoxia was shown to promote the expression of many lipoprotein receptors, as LDL-R, 80 
LRP1, VLDL-R and SR-BI [16] (see Box 3). In addition, the acidic environment increases the 81 
affinity of LDL for PGs, which favors LDL uptake by endocytosis [16]. Furthermore, PG-bound 82 
LDL are entrapped in the extracellular space, where they can undergo oxidation that 83 
increases LDL affinity to scavenger receptors and triggers pro-inflammatory and pro-oxidant 84 
cascades [17]. 85 
The relevance of cholesterol for proliferating cancer cells is supported by three main findings. 86 
First, cholesterol accumulates in cancer cells due to the upregulation of its synthesis and 87 
uptake [18-21] (Figure 2). Since unesterified cholesterol is toxic, it is quickly esterified in the 88 
cytosol by ACAT and stored in lipid droplets (LDs), which aberrantly accumulate in tumor 89 
cells [22]. Second, the inhibition of the SREBP pathway exerts antiproliferative and 90 
antimetastatic effects [20]. Third, when cholesterol is rapidly removed from cell membranes, 91 
as by methyl--cyclodextrin (MCD, an acceptor of cholesterol through passive diffusion), cell 92 
survival is impaired [23-25]. 93 
 94 
Structural and functional role of cholesterol in the cell membrane 95 
Cholesterol regulates the fluidity of the cell membrane and its distribution is not 96 
homogeneous; lipid rafts are sub-domains of the membrane particularly enriched in 97 
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cholesterol along with glycosphingolipids and sphingomyelin [9]. Lipid rafts have a key role in 98 
signal transduction, since many types of proteins are recruited to these domains, as 99 
glycosylphosphatidylinositol-anchored proteins, prenylated and acylated proteins, and 100 
transmembrane receptors [26]. Lipid rafts act as concentrating platforms for receptors 101 
activated by ligand binding; the activation leads to rafts’ clustering, which favors the 102 
interaction among the various members of a signaling complex by close proximity [26]. 103 
Interestingly, many receptors for growth factors (as epidermal growth factors, insulin-like 104 
growth factor 1 and vascular endothelial growth factor) are located in lipid rafts and an 105 
enrichment in cholesterol was shown to increase the activation of downstream PI3K/Akt and 106 
ERK1/2 pathways, likely supporting cancer cell proliferation and migration. On the contrary, 107 
when cholesterol is removed from lipid rafts (as by MCD or HDL), receptors are internalized 108 
and signaling events blunted [24,25]. 109 
 110 
Intra-tumor formation of cholesterol metabolites 111 
The local production of dihydrotestosterone and 17-estradiol from cholesterol by 5-112 
reductases and aromatases could explain the progression of PCa and BC even with the very 113 
low levels of circulating hormones achieved during deprivation therapies. Locally produced 114 
hormones can activate their cognate receptors, supporting cancer cell proliferation [27,28]; 115 
accordingly, 5-reductase and aromatase inhibitors represent a therapeutic strategy for the 116 
management of hormone-dependent cancers [29]. Likewise, intra-tumor hormone synthesis 117 
from cholesterol is upregulated in other endocrine cancers, as adrenocortical and ovarian 118 
carcinomas [30,31]. 119 
Intracellular cholesterol metabolism can also lead to the generation of a wide spectrum of 120 
oxysterols through the action of the cytochrome P450 family enzymes (CYPs). Interestingly, 121 
compared to parental non-tumor cells, PCa and BC cells could present with an altered 122 
expression of CYPs, leading to a different pattern of cholesterol metabolites; consequently, 123 
some cholesterol metabolites are overproduced in cancer cells, while other are generated in 124 
lower amounts [32]. Oxysterols are endogenous ligands of LXRs and are generally believed 125 
to exert anti-proliferative actions; LXR activation, besides regulating cholesterol homeostasis, 126 
triggers anti-inflammatory pathways in cancer and stromal cells [10,33]. For example, LXR 127 
agonists were shown to induce the release of anti-inflammatory interferon  from 128 
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macrophages and T cells [34]. In addition, LXRs can increase the expression of 129 
sulfotransferases, leading to steroid inactivation [35]. The activity of oxysterols on cancer cells 130 
extends beyond LXR activation. Indeed, 7-ketocholesterol (as unsaturated fatty acids) was 131 
shown to act as ligand of the so-called antiestrogen binding site (AEBS); 5,6- and 5,6-132 
epoxycholesterol and their condensation product with histamine, dendrogenin A, also 133 
displayed high AEBS affinity [36]. On the contrary, some oxysterols could contribute to tumor 134 
growth, as 27-hydroxycholesterol. Indeed, it was shown to specifically increase the growth of 135 
ER-positive BC cancer cells by acting as an ER agonist [32]. Interestingly, 27-136 
hydroxycholesterol accumulation has been described in ER-positive BC due to the 137 
downregulation of CYP7B1, blunting the transcription of many LXR-regulated genes and in 138 
particular of ABCA1 [32]. Contrasting results were obtained for 27-hydroxycholesterol on PCa 139 
cells [37,38]. 140 
Fatty acid metabolism by cancer and immune cells in the TME can also lead to the generation 141 
of bioactive molecules, such as eicosanoids [39]. These molecules are produced from 142 
arachidonic acid and other polyunsaturated fatty acids by the action of lipoxygenases and 143 
cyclooxygenases. Their role in cancer is still in debate since they were variably associated 144 
with cancer cell proliferation; indeed, while some eicosanoids may act as tumor suppressors 145 
(as omega-3 fatty acids and resolvins), others were shown to promote the survival and the 146 
proliferation of cancer cells [39]. In particular, prostaglandin E2 levels are elevated in several 147 
human malignancies, including BC, PCa and ovarian cancer, and were associated with poor 148 
prognosis and resistance to chemotherapy and radiotherapy [40,41]. Thromboxane A2 149 
(TXA2) is also increasingly implicated in cancer progression, especially in triple negative BC. 150 
The binding of TXA2 to its receptor (thromboxane receptor, TP) enhances BC cell migration 151 
and invasion by triggering Rho activation [29]. Through the same mechanism, TP activation 152 
induced cytoskeletal reorganization of PCa cells [42]. On the contrary, resolvins may help to 153 
lower the risk of developing cancer [43]. These bioactive lipids, derived from the omega-3 154 
fatty acids eicosapentaenoic acid and docosahexaenoic acid, are key players in the resolution 155 
of inflammation. In multiple tumor types, resolvins were shown to reduce tumor growth, neo-156 
angiogenesis, metastatization and to revert the deactivation of natural killer (NK) cells [44]. 157 
 158 
Lipid metabolites for protein modification 159 
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Along the mevalonate pathway, isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-160 
pyrophosphate) are produced, which are needed for prenylation, a post-translational 161 
modification of proteins. Prenylation provides the target protein with a hydrophobic C 162 
terminus, which guides its localization within the cell, for example to the lipid rafts, favoring 163 
protein-protein interactions [45]. Many prenylated proteins are involved in cell signaling, as 164 
small GTP binding proteins. Among these, the oncogene RAS is the most studied and a 165 
reduction of isoprenoid production, as by farnesyltransferase inhibitors, is under investigation 166 
with promising results in aggressive BC [46]. 167 
Fatty acids are also involved in protein modification, as some proteins undergo myristoylation 168 
or palmitoylation [47,48]. Again, many of the target proteins are crucial components of 169 
signaling pathways and the modification with fatty acids promotes their binding to the 170 
membrane for proper localization and function. Well-characterized targets include many 171 
oncogene products, such as the tyrosine kinase Src [47,48]. 172 
 173 
Lipoproteins as pharmacological targets? 174 
Epidemiologic evidence 175 
Several retrospective studies investigated the relationship between plasma levels of 176 
lipids/lipoproteins and the incidence of different cancer types. To date, conflicting results were 177 
obtained, since positive, negative or no relationships were found [49,50]. In the REduction by 178 
DUtasteride of prostate Cancer Events (REDUCE) trial, total cholesterol was positively 179 
associated with an increased risk of high-grade PCa (5% higher for 10 mg/dl), but not with 180 
low-grade one. HDL-C levels were also positively associated with overall risk of PCa (8% 181 
higher for 10 mg/dl) [51]. However, in the same trial, men with high HDL-C displayed reduced 182 
prostate inflammation [52]. On the contrary, in the Alpha-Tocopherol, Beta-Carotene Cancer 183 
Prevention (ATBC) study, while the positive association between total cholesterol and the risk 184 
of advanced PCa was confirmed, HDL-C was negatively associated with PCa risk [53]. The 185 
association between plasma lipids and the risk of cancer was also investigated in prospective 186 
studies. Large meta-analyses excluded the association between plasma lipids and the risk of 187 
PCa and ovarian cancer, but HDL-C was negatively associated with BC risk [54-56]. 188 
Mendelian randomization studies were performed to address the causal link between 189 
plasma lipids and PCa or BC risk. No association of plasma lipids with PCa risk was found, 190 
with a weak evidence that higher LDL-C and triglyceride levels increased aggressive PCa risk 191 
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[57]. On the contrary, genetically raised LDL-C levels were associated with higher risk of BC, 192 
especially of the ER-positive type [58]. The same relationship was found for elevated HDL-C, 193 
but it should be noted that only the effect of CETP variants was assessed, and inhibiting 194 
CETP is debated for the possible accumulation of dysfunctional HDL [59]. The role of dietary 195 
lipids on cancer risk is also debated, since a lipid-rich diet could be indicative of an unhealthy 196 
lifestyle. In addition, a significant association between dietary cholesterol intake and the risk 197 
of BC was detected only with very high intakes [60]. Another approach to address the 198 
relationship between plasma lipids and the incidence of cancer is to assess the association 199 
with statins. In two recent meta-analysis, statins were shown to have a neutral effect on both 200 
PCa and BC incidence [61,62]. Consistently, the Cholesterol Treatment Trialists' 201 
Collaboration showed no evidence of any effect of reducing cholesterol with long-term statin 202 
therapy on cancer incidence or mortality [63]. To explain the inconsistency between studies, 203 
the type of cancer and the time at which lipids were assessed could act as confounding 204 
factors. The stage of the disease and the consequent therapies can affect the levels of 205 
circulating lipids; plasma lipids, especially HDL-C levels, are reduced in several cancer 206 
patients during active disease, as in those having breast, ovarian, prostate, colon and 207 
pancreatic carcinomas [64]. The large HDL2 subclass is particularly reduced [65].The 208 
predictive power of low HDL-C and apoA-I levels was so strong that apoA-I was included in 209 
the screening for ovarian cancer with other traditional biomarkers [66]. The mechanisms 210 
beyond HDL-C reduction are not fully understood. Since the liver and the intestine are 211 
responsible for the synthesis of apoA-I and its lipidation by ABCA1, malignancies at these 212 
organs can directly impaired HDL biogenesis. As shown in many inflammatory states, pro-213 
inflammatory cytokines inhibit hepatic apoA-I expression and, thus, the cancer-related 214 
sustained inflammation can repress HDL biogenesis by the same mechanism [67]. Finally, the 215 
hepatic expression of several proteins involved in lipoprotein metabolism can be modulated 216 
by inflammation and cancer, including LCAT; thus, HDL-C reduction could be part of a more 217 
complex alteration of lipoprotein metabolism induced by cancer [67]. 218 
The association between plasma lipids and the recurrence of cancer has been firmly 219 
established. Plasma levels of cholesterol are positively associated with a higher recurrence 220 
rate of BC and statin use was associated with extended recurrence free survival time [68]. 221 
This protective effect was confirmed in women with hormone receptor-positive early-stage 222 
breast cancer taking statins during adjuvant endocrine therapy [69]. Plasma levels of HDL-C 223 
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are inversely related to the prognosis; in a recent meta-analysis including both retrospective 224 
and prospective studies, patients with higher HDL-C had 37% reduced risk of death and 35% 225 
reduced risk of disease relapse compared to patients with lower HDL-C [70].  226 
 227 
Targeting apoB-containing lipoproteins 228 
The use of hyperlipidemic mice (apoE-/- model) fed a high fat/high cholesterol diet (HFHC) can 229 
help to address the impact of increased plasma levels of apoB-containing lipoproteins on the 230 
development of hormone-dependent cancers. The injection of non-metastatic Met-1 and 231 
metastatic Mvt-1 mammary cancer cells in apoE-/- mice resulted in larger tumors and in a 232 
greater number of lung metastases compared to wild-type mice [71]. Interestingly, the graft 233 
with BC cell lines representative of triple-negative or HER2-enriched tumors in hyperlipidemic 234 
mice resulted in reduced tumor growth when the LDL-R was silenced [72]. Consistently, LDL 235 
increased the proliferation and migration of ER-negative BC cells but not of ER-positive ones, 236 
which also accumulated less CEs than ER-negative cells [73]. These data suggest that ER-237 
negative BC may be more sensitive to cell cholesterol-lowering strategies. Regarding PCa, 238 
mice fed a HFHC diet developed larger tumors after injection of androgen-dependent LNCaP 239 
cells compared to mice under chow diet [24]. In addition, the HFHC diet accelerated tumor 240 
incidence and burden compared to chow diet in the TRAMP mouse, a model of PCa [74]. 241 
These data are supported by several in vitro studies. VLDL, but not LDL, increased the 242 
formation of BC cell mammospheres, an estimate of stem cell/early progenitor activity, and 243 
cell resistance to radiotherapy, likely due to a modulation of intracellular cholesterol content 244 
[75]. Consistently, the treatment of aggressive and metastatic BC cells with statins was 245 
associated with an increased sensitivity to radiation therapy [75]. The in vivo relevance of 246 
these findings was supported by the shorter recurrence-free period in patients with elevated 247 
VLDL-C levels, which suggests a systemic effect of statins through the reduction of circulating 248 
apoB-containing lipoproteins [75]. Oxidized LDL (oxLDL), but not native LDL, increased the 249 
proliferation of ovarian cancer cells and decreased their sensitivity to cisplatin, an effect 250 
prevented by statins and by LXR activation [76]. OxLDL could act through the binding with its 251 
lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which stimulates the 252 
expression of pro-adhesive, pro-inflammatory and proangiogenic factors in vascular 253 
endothelial cells and macrophages. LOX-1 upregulation was reported in several different 254 
types of cancer, including PCa. Here, its activation by oxLDL promoted epithelial to 255 
10 
 
mesenchymal transition and increased tumor growth in nude mice [77]. In BC cell lines, LOX-256 
1 inhibition blunted inflammatory and hypoxic responses [78]. Finally, apoB-containing 257 
lipoproteins and adipocytes could deliver free fatty acids to cancer cells by the action of 258 
locally expressed LPL; BCs are generally positive for LPL and its expression increased cell 259 
proliferation [79]. Moreover, adipocytes can directly provide cancer cells with fatty acids. 260 
Indeed, cancer cells can stimulate TG lipolysis by the adipose triglyceride lipase/hormone-261 
sensitive lipase axis in adipocytes [80]. Adipocytes were shown to support the proliferation 262 
and invasiveness of highly differentiated and hormone-dependent cancers more than of 263 
poorly differentiated ones [81]. 264 
Recently, the use of statins in the management of cancer has been questioned. Statins are 265 
mainly taken up by the liver, with little amounts reaching other organs and tissues. In addition, 266 
the inhibition of cholesterol synthesis by statins induces a SREBP-mediated increase of LDL-267 
R expression. Thus, statins could have positive systemic effects on tumors by reducing 268 
plasma levels of LDL-C but could increase LDL-R-mediated cholesterol uptake by cancer 269 
cells. On this line, Caro-Maldonado et al. recently showed that statins increased PCa 270 
aggressiveness in vivo [82]. On the contrary, the silencing of LDL-R gave promising results in 271 
pancreatic adenocarcinoma, in HER2-enriched and triple negative BC cells [72,83]. Similar 272 
results were obtained when ACAT was inhibited to reduce intracellular CE stores in LDs, as in 273 
PCa, BC and adrenocortical carcinoma [22,73,84-86]. 274 
Among the apoB-containing lipoproteins, Lp(a) could exert a peculiar role on cancer biology. 275 
Indeed, it was shown to inhibit angiogenesis, thus causing delayed tumor growth and 276 
metastasis formation in models of lung and colorectal cancers; the effect was ascribed to the 277 
presence of repeated kringles in the apo(a) structure, a typical feature of angiostatin-related 278 
proteins [87]. 279 
 280 
Targeting the HDL system 281 
Animal studies provided proofs of a causal link between HDL and cancer risk. When HDL-C 282 
levels were increased by genetic manipulation (as in the human apoA-I transgenic mice) or by 283 
direct infusion of apoA-I, the growth of lung, melanoma or ovarian cancer cells after xenograft 284 
was reduced compared to control animals [88]. Consistently, in apoA-I-/- mice, in which HDL-C 285 
levels are dramatically reduced, tumor development increased compared to wild-type animals 286 
11 
 
[88]. More interestingly, apoA-I infusion after the development of the tumor mass resulted in 287 
tumor shrinkage [88]. 288 
In vitro studies provided some mechanistic insights. When BC cells were incubated with HDL, 289 
the formation of mammospheres was inhibited and their sensitivity to radiation therapy 290 
increased, an effect due to a reduced cholesterol content [75]. Whether this reduction was 291 
ascribed to a depletion of cell membrane content or of intracellular CE stores in LDs was not 292 
addressed. It could be speculated that, given the continual cycle of hydrolysis and 293 
esterification of CE in LDs, the removal of unesterified cholesterol from the cell membrane 294 
promoted by HDL could shift the balance towards CE hydrolysis with a consequent LD 295 
depletion, as shown in macrophages [89]. In PCa cell lines, HDL blunted basal and H2O2-296 
induced oxidative stress and reduced ROS-induced proliferation, with a role for both the 297 
protein and phospholipid components [90]. 298 
On the contrary, some studies showed a SR-BI-dependent increased growth of cancer cells 299 
incubated with HDL [91,92]. In this context, large CE-enriched HDL could represent a better 300 
substrate for SR-BI-mediated cholesterol influx supporting cancer cell growth. It has to be 301 
pointed out that HDL could become dysfunctional in several pathologic conditions, including 302 
inflammatory states, metabolic diseases and cancer, due to modifications of their protein and 303 
lipid cargo [64,93]. Consistently, the proliferation of the BC cell line MCF-7 was induced by 304 
HDL isolated from type 2 diabetic patients, but not by HDL from healthy controls. Only HDL 305 
from diabetic patients were able to promote BC metastasis by increasing the adhesion of 306 
cancer cells to endothelial cells [94,95]. 307 
Two approaches can be used to raise circulating HDL. The first is to improve HDL biogenesis 308 
or to limit their catabolism. To date, no drug specifically increases HDL-C levels. Fibrates and 309 
niacin have multiple effects on lipid metabolism including the increase of HDL biogenesis, but 310 
their role in cancer management has not been investigated. CETP inhibitors specifically 311 
increase HDL-C, but their development is hampered by the lack of a clear cardiovascular 312 
benefit, together with the possibility to accumulate dysfunctional HDL [59]. The second 313 
approach is to infuse reconstituted HDL (rHDL), discoidal particles made of phospholipids and 314 
apoA-I (or synthetic apoA-I mimetic peptides) that were shown to retain the atheroprotective 315 
activities of HDL [96]. Reconstituted HDL have been already tested in multiple in vivo and in 316 
vitro tumor models [97]. Among the underlying mechanisms, anti-inflammatory activities, 317 
inhibition of angiogenesis, abrogation of growth factor-induced proliferation, migration and 318 
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invasion were described [97]. Multiple positive effects of rHDL on TME cellular composition 319 
were also shown, as a reduced content of myeloid-derived suppressor cells and the 320 
accumulation of M1 macrophages and cytotoxic CD8+ T cells [88]. Some of these effects 321 
were detected with direct apoA-I or apoA-I mimetic peptide administration, suggesting an anti-322 
tumor activity of HDL apolipoprotein components [88]; however, it cannot be fully excluded 323 
that apoA-I or its peptides could rapidly acquire phospholipids and cholesterol in the 324 
circulation, thus generating HDL-like particles. 325 
 326 
HDL-like particles for drug delivery 327 
Reconstituted HDL are also under development as drug carriers for tumor targeting. They 328 
accumulate within the tumor mass by unselective mechanisms (as nanoparticles do through 329 
the leaky vasculature) and by the specific interaction with SR-BI. This receptor is highly 330 
expressed in multiple cancers and allows cytosolic delivery of the payload bypassing the 331 
endolysosomal route [98]. Unlike exogenous nanoparticles, rHDL containing apoA-I are non-332 
immunogenic and have long circulation half-life. In addition, the small diameter (<14 nm) 333 
allows a deeper penetration of rHDL into the tumor mass if compared to nanoparticles, which 334 
is crucial for the treatment of solid tumors [99]. 335 
Several types of molecules can be incorporated into rHDL as small molecule drugs, small 336 
interfering RNAs, photothermal agents or fluorescent dyes for imaging [98]. The composition 337 
and the particle size/shape of rHDL can be tailored according to the type of molecule to be 338 
carried and the tumor to be targeted. For example, spherical rHDL were used for the 339 
encapsulation of highly hydrophobic drugs into the particle core: by this way paclitaxel and 340 
valrubicin were successfully delivered to PCa, triple-negative BC or ovarian cancer cells in 341 
vitro and in vivo [100-102]. 342 
 343 
Concluding remarks and future perspectives 344 
Targeting the lipoprotein system is becoming an attractive approach to develop novel 345 
therapeutic strategies for the management of hormone-dependent cancers. The conflicting 346 
results of epidemiological and interventional studies suggest that the availability of 347 
lipoproteins in the TME is likely more relevant than their circulating levels. In this context, 348 
statins use seems not a promising strategy due to their preferential hepatic distribution and 349 
upregulation of the LDL-R expression. On the contrary, targeted repression of the LDL-R in 350 
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cancer cells, as by genetic silencing, already generated positive results in different types of 351 
cancer. Another approach is to increase the efficiency of the HDL system in promoting lipid 352 
removal, as by the infusion of rHDL to rise the endogenous HDL pool. This approach has 353 
some advantages. Reconstituted HDL are already under clinical development for patients with 354 
acute coronary syndrome [96]. Their protein and lipid composition can be manipulated to 355 
optimize their function. In addition, rHDL can be used as carriers of other bioactive molecules, 356 
ranging from nucleic acids to drugs [98]. 357 
Overall, targeting lipid metabolism in the TME should be considered as an adjuvant strategy 358 
to increase cancer cell sensitivity to classical therapeutic agents.  359 
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Figure legends 360 
Figure 1. Cholesterol metabolism and function in cancer cells. 361 
Cholesterol can be synthetized from acetyl-CoA through the mevalonate pathway or it can be 362 
taken up from lipoproteins in the tumor microenvironment. Indeed, very low density 363 
lipoproteins (VLDL), low density lipoproteins (LDL) and their remnants can undergo 364 
endocytosis mediated by the LDL-receptor family. On the contrary, high density lipoproteins 365 
(HDL) promote cholesterol efflux from cancer cells through their interaction with ATP-binding 366 
cassette transporters A1 and G1 (ABCA1, ABCG1) or with the scavenger receptor type BI 367 
(SR-BI). Since SR-BI mediates a facilitated diffusion of cholesterol according to concentration 368 
gradient, it could also favor lipid influx. Cholesterol is a key component of lipid rafts, and it can 369 
be converted to hormones and oxysterols. Created with BioRender. 370 
 371 
Figure 2. Lipid homeostasis in cancer cells. 372 
Cellular homeostasis of lipids is regulated by sterol regulatory element-binding proteins 373 
(SREBPs) and liver X receptors (LXRs), according to the metabolic needs of the cell. In 374 
cancer cells, the balance between SREBPs and LXRs is lost, with an hyperactivation of 375 
SREBPs and LXR inhibition. Consequently, cholesterol and fatty acid synthesis is 376 
upregulated, as the uptake of lipoproteins; on the contrary, cholesterol efflux is blunted. 377 
Created with BioRender.  378 
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Box 1. Incidence and classification of breast and prostate cancers 379 
Breast cancer is the most common cancer in women and the second most common cancer 380 
overall. Age-standardized incidence rate in Europe, North America and Australia is >70 cases 381 
per 100.000 women [103]. BC is highly heterogeneous and it is currently classified according 382 
to histopathological features and gene expression profiling into luminal A, luminal B, HER2-383 
enriched and basal-like (commonly referred to as triple-negative) (Table 1) [104]. This 384 
classification could predict the clinical outcome and the response to therapeutic interventions. 385 
Luminal BCs, which are positive to estrogen and/or progesterone receptors, will likely respond 386 
to hormone therapy; HER2-targeted treatments are indicated in HER2-enriched BC, while 387 
conventional chemotherapy is used for basal-like BC [1]. 388 
Table 1. Classification of BC 389 
 ER/PR HER2 Ki67 
Luminal A + - <14% 
Luminal B + - >14% 
HER2-enriched - +  
Basal-like - -  
ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor type II 390 
receptor; Ki67, nuclear protein used as a proliferation marker. 391 
 392 
Prostate cancer is the most common cancer in men and the fourth most common cancer 393 
overall. Age-standardized incidence rate in Europe, North America and Australia is >60 cases 394 
per 100.000 men [103]. The morphological classification of PCa has been significantly 395 
modified in the last decade [105]. The new grading system into 5 categories is based on the 396 
relative prevalence of (i) well-formed glands, (ii) poorly formed, fused or cribriform glands, (iii) 397 
lack of gland formation or necrosis. This classification is integrated with prostate-specific 398 
antigen levels and with the following information: (i) localization and size of the tumor mass, 399 
(ii) whether the cancer has spread to nearby lymph nodes, (iii) whether the cancer has 400 
metastasized. The final result is PCa staging from I to IV, which guides the selection of 401 
treatment approach among active surveillance, prostatectomy, radiotherapy, hormone-402 
deprivation therapy and chemotherapy for hormone-refractory tumors [2]. 403 
 404 
16 
 
Box 2. Energetic metabolism of cancer cells 405 
Normal cells rely on fatty acids oxidation (FAO) and mitochondrial oxidative phosphorylation 406 
(OXPHOS) for acetyl-CoA and ATP production. Cancer cells rewire their energetic machinery 407 
from OXPHOS to anaerobic glycolysis, especially in the hypoxic core of solid tumors; 408 
glycolysis occurs even in the presence of oxygen (the Warburg effect), generating large 409 
amounts of lactate that contributes to TME acidity [106]. Altered tumor cell metabolism affects 410 
TME cells; in particular, the release of lactate and TME acidification inhibit dendritic and T cell 411 
activation, thus favoring tumor immune escape [107]. Interestingly, ATP is still produced in the 412 
mitochondria of tumor cells and mitochondrial tricarboxylic acid cycle intermediates are 413 
needed as precursors for macromolecule synthesis, as citrate for lipid synthesis and 414 
oxaloacetate for nucleotide synthesis [106]. In this context, FAO is the main source of acetyl-415 
CoA for mitochondrial OXPHOS. 416 
Interestingly, low rates of glycolysis were found in PCa and, indeed, PCa cells were shown to 417 
have a dominant uptake of fatty acids over glucose [108]. In addition, stromal cells and, most 418 
interestingly, cancer stem cells still rely on OXPHOS for energy production. The latter are 419 
now widely considered having a strong metastatic potential and resistance to radiotherapy 420 
and chemotherapy [109]. 421 
 422 
Box 3. Structure and metabolism of lipoproteins 423 
Lipoproteins carry lipids in the circulation; they are composed by a core of hydrophobic 424 
triglycerides (TG) and cholesteryl esters (CE), surrounded by a double layer of phospholipids, 425 
unesterified cholesterol and apolipoproteins. According to their density and apolipoprotein 426 
composition, they are classified into chylomicrons, very low density lipoproteins (VLDL), low 427 
density lipoproteins (LDL) and high density lipoproteins (HDL), which have distinct roles in 428 
lipid metabolism [110]. 429 
Chylomicrons are secreted by intestinal epithelial cells and transport dietary lipids to the liver. 430 
They are the largest and less dense lipoproteins, because their lipid cargo is mainly 431 
composed by TG. Their main protein component is apoB-48. After TG hydrolysis by 432 
lipoprotein lipase (LPL) and the release of free fatty acids to peripheral tissues, the liver takes 433 
up chylomicron remnants through the interaction of apoE with members of the LDL receptor 434 
family (LDL-R and the LDL-related receptor protein, LRP-1). 435 
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VLDL are secreted by the liver and are enriched in TG; their main protein component is apoB-436 
100. After TG hydrolysis by LPL, generated remnants are converted into LDL, whose core is 437 
mainly composed by CE. LDL deliver cholesterol to peripheral tissues by the interaction of 438 
apoB-100 with LDL-R. Circulating LDL can be taken up by the liver through the same 439 
mechanism. The liver also secretes lipoprotein (a) (Lp(a)), which is a LDL-like particle with 440 
one molecule of apo(a) covalently bound to apoB. Apo(a) is structurally similar to 441 
plasminogen, with multiple copies of kringle domains, but lacks the fibrinolytic activity; thus, 442 
by competing with plasminogen, apo(a) could exert a potential pro-thrombotic effect [111]. 443 
The biogenesis of HDL is more complex [112]. Their main protein component, apoA-I, is 444 
secreted by the liver and by the intestine and is rapidly lipidated by the interaction with the 445 
ABC transporter A1 (ABCA1) and the formation of discoidal nascent HDL. Further uptake of 446 
cholesterol and phospholipids and cholesterol esterification by lecithin:cholesterol 447 
acyltransferase (LCAT) leads to the formation of mature spherical HDL. In addition, HDL can 448 
be generated from the dissociation of lipids and apoA-I during the remodeling of apoB-449 
containing lipoproteins. The main role of HDL is to deliver cholesterol to the liver. The first 450 
step of this process is the efflux of cholesterol and phospholipids from cell membranes to HDL 451 
or apoA-I [13]. Cholesterol efflux can (i) occur by passive diffusion, (ii) be actively promoted 452 
by ABCA1 and ABCG1, or (iii) occur by diffusion facilitated by the scavenger receptor type BI 453 
(SR-BI). Thus, according to the gradient concentration between cell membranes and HDL, 454 
SR-BI can mediate cholesterol efflux or influx. Once cholesterol is esterified by LCAT, HDL 455 
can directly deliver CE to the liver through hepatic SR-BI, which mediates the selective uptake 456 
of CE without HDL endocytosis. However, in humans the majority of CE is indirectly routed to 457 
the liver by the action of CE transfer protein (CETP), which mediates the exchange of CE for 458 
TG between HDL and apoB-containing lipoproteins. CE are then taken up by the liver through 459 
the endocytosis of apoB-containing lipoproteins by LDL-R and LRP-1. 460 
 461 
Box 4. Effects of lipoproteins on cell metabolism: insights from cardiovascular 462 
diseases 463 
Most of the available evidence on the role of lipoproteins in cell metabolism comes from the 464 
field of vascular biology and atherosclerosis. Lipoproteins can be divided into pro-465 
atherogenic (apoB-containing lipoproteins, i.e. VLDL, LDL, Lp(a) and TG-rich remnants) and 466 
anti-atherogenic ones (HDL). ApoB-containing lipoproteins promote the development of 467 
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atherosclerosis because they mediate the transport of lipids from the liver to peripheral 468 
tissues, including the arterial wall [113]. On the contrary, HDL are the main acceptors of 469 
cholesterol from peripheral tissues and mediate its transport to the liver for excretion, among 470 
the so-called “reverse cholesterol transport” [13]. While systemic levels of lipids can widely 471 
vary in different physiologic and pathologic conditions, their cell content is tightly regulated 472 
[114,115]. Cells can synthesize cholesterol and fatty acids or lipids can be taken up from 473 
circulating lipoproteins. However, excess cholesterol is toxic for the cells and, consequently, it 474 
is removed through efflux towards extracellular acceptors as HDL, or it is esterified by acyl-475 
coA:cholesterol acyltransferase (ACAT) and stored in cytosolic lipid droplets (LDs); the same 476 
happens to fatty acids, which are stored in LDs as TG. The cellular sensors of cholesterol and 477 
fatty acid content, that regulate the pathways described above, are the sterol regulatory 478 
element binding proteins (SREBPs) and the liver X receptors (LXRs) [114,115]. When 479 
cells need cholesterol and/or fatty acids, SREPBs are activated, promoting lipid synthesis and 480 
uptake, while LXRs are inhibited. On the contrary, when intracellular levels of lipids are 481 
increased, SREBPs are switched off and LXRs activated. LXRs favor lipid efflux by increasing 482 
the expression of the ABC transporters, and they decrease lipoprotein uptake through the 483 
downregulation of the LDL-R (see box 3) [116,117]. However, scavenger receptors, as the 484 
cluster of differentiation 36 (CD36), can mediate an unregulated uptake of lipoproteins and, 485 
consequently, an excessive lipid accumulation in macrophages within the arterial wall [118]. 486 
The role of lipoproteins is complex and not limited to the in/out transport of lipids. ApoB-487 
containing lipoproteins, including TG-rich remnants, exert pro-inflammatory activities on 488 
different cell types, especially after oxidation [17]. On the contrary, HDL were shown to exert 489 
a series of anti-inflammatory and antioxidant activities on several cells involved in the 490 
atherosclerotic process [119]. In addition, lipoproteins, especially HDL, can act as carriers of 491 
several bioactive molecules, including miRNAs [120].  492 
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Glossary 493 
Antiestrogen binding site (AEBS): It has been identified as a microsomal high-affinity 494 
binding site for the estrogen antagonist tamoxifen, distinct from the estrogen receptor. It does 495 
not bind estrogens. AEBS is composed by the 3-hydroxysterol-8-7-isomerase (D8D7I) and 496 
the 7-dehydrocholesterol reductase (DHCR7) enzymes, which are involved in cholesterol 497 
synthesis. 498 
Atherosclerosis: Pathologic process characterized by the accumulation of lipids and cells in 499 
the arterial wall, causing a progressive narrowing of the arterial lumen. 500 
Cancer stem cells: Cancer cells expressing markers of hematopoietic stem cells, which are 501 
able to initiate tumors in vivo. Their presence was shown in all solid tumors. 502 
Cytochrome P450 enzymes (CYPs): A family of oxidative enzymes involved in the synthesis 503 
and metabolism of various molecules within the cells. They are essential for the metabolism 504 
and excretion of xenobiotics. The liver is enriched in CYPs, but they are expressed 505 
throughout the body. 506 
Glycolysis: A sequence of reactions that converts glucose into pyruvate. 507 
Hypoxia: A condition in which local oxygen supply is insufficient for cell metabolic 508 
requirements. The TME becomes hypoxic due to the fast proliferation of cancer cells that is 509 
not supported by an adequate formation of novel vessels. When the tumor mass grows, 510 
oxygen delivered by blood is quickly consumed by cancer cells that are closest to the vessels, 511 
thus hampering its diffusion into the tumor mass. Consequently, most solid tumors display 512 
regions that are permanently or transiently in hypoxic conditions. 513 
Lipid droplets: Intracellular stores of fatty acids and cholesterol in the form of neutral lipids. 514 
They are hydrolyzed in the cytosol or in the lysosomes to meet cell energy requirements. 515 
Liver X receptors (LXRs): Nuclear receptors activated by oxysterols. LXR is mainly 516 
expressed in the liver, while LXR is ubiquitously expressed. LXRs play a crucial role in cell 517 
metabolism since they control the transcription of genes involved in cholesterol, fatty acid and 518 
glucose homeostasis. 519 
Mendelian randomization studies: Epidemiologic studies in which genetic variations are 520 
used to investigate the causal link between a potentially modifiable risk factor and disease 521 
outcome. 522 
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Oxysterols: Oxygenated derivatives of cholesterol produced by enzymatic or nonenzymatic 523 
peroxidation. They are intermediates or end-products of cholesterol excretion by its 524 
transformation into water-soluble bile acids. Oxysterols regulate cholesterol homeostasis and 525 
can exert potent effects on several biological processes. 526 
RAS: Oncogene coding for small GTP binding proteins involved in the regulation of the cell 527 
proliferation and death. Members of the RAS family include KRAS, HRAS, and NRAS. RAS is 528 
frequently mutated in human cancers. 529 
Statins: Lipid-lowering agents that inhibit the 3-hydroxy-3-methyglutaryl coenzyme A (HMG-530 
CoA) reductase, the rate-limiting enzyme of cholesterol synthesis along the mevalonate 531 
pathway. 532 
Sterol regulatory element-binding proteins (SREBPs): Family of transcription factors 533 
consisting of two genes, SREBF1 and SREBF2, that encode for three different proteins: 534 
SREBP1a, SREBP1c and SREBP2. They regulate the transcription of genes involved in 535 
cholesterol biosynthesis and uptake, and fatty acid biosynthesis.  536 
21 
 
References 537 
 538 
1. Senkus, E. et al. (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for 539 
diagnosis, treatment and follow-up. Ann. Oncol. 26 Suppl 5, v8-30 540 
2. Cornford, P. et al. (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: 541 
Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur. Urol. 71, 542 
630-642 543 
3. Quail, D.F. and Joyce, J.A. (2013) Microenvironmental regulation of tumor progression and 544 
metastasis. Nat. Med. 19, 1423-1437 545 
4. Hanahan, D. and Coussens, L.M. (2012) Accessories to the crime: functions of cells 546 
recruited to the tumor microenvironment. Cancer Cell 21, 309-322 547 
5. Mittal, S. et al. (2018) The breast tumor microenvironment: role in cancer development, 548 
progression and response to therapy. Expert. Rev. Mol. Diagn. 18, 227-243 549 
6. Finak, G. et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. 550 
Nat. Med. 14, 518-527 551 
7. Farmer, P. et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant 552 
chemotherapy in breast cancer. Nat. Med. 15, 68-74 553 
8. Grivennikov, S.I. et al. (2010) Immunity, inflammation, and cancer. Cell 140, 883-899 554 
9. Pike, L.J. (2003) Lipid rafts: bringing order to chaos. J. Lipid Res. 44, 655-667 555 
10. Schroepfer, G.J., Jr. (2000) Oxysterols: modulators of cholesterol metabolism and other 556 
processes. Physiol Rev. 80, 361-554 557 
11. Krycer, J.R. and Brown, A.J. (2013) Cholesterol accumulation in prostate cancer: a classic 558 
observation from a modern perspective. Biochim. Biophys. Acta 1835, 219-229 559 
12. Menard, J.A. et al. (2018) Functional role of extracellular vesicles and lipoproteins in the 560 
tumour microenvironment. Philos. Trans. R. Soc. Lond B Biol. Sci. 373 561 
13. Rosenson, R.S. et al. (2012) Cholesterol efflux and atheroprotection: advancing the 562 
concept of reverse cholesterol transport. Circulation 125, 1905-1919 563 
14. Chen, Y. and Hughes-Fulford, M. (2001) Human prostate cancer cells lack feedback 564 
regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer 91, 41-565 
45 566 
15. Chuu, C.P. et al. (2006) Inhibition of tumor growth and progression of LNCaP prostate 567 
cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 66, 6482-568 
6486 569 
22 
 
16. Menard, J.A. et al. (2016) Metastasis Stimulation by Hypoxia and Acidosis-Induced 570 
Extracellular Lipid Uptake Is Mediated by Proteoglycan-Dependent Endocytosis. Cancer Res. 571 
76, 4828-4840 572 
17. Pirillo, A. et al. (2013) LOX-1, OxLDL, and atherosclerosis. Mediators. Inflamm. 2013, 573 
152786 574 
18. de Gonzalo-Calvo, D. et al. (2015) Intratumor cholesteryl ester accumulation is associated 575 
with human breast cancer proliferation and aggressive potential: a molecular and 576 
clinicopathological study. BMC. Cancer 15, 460 577 
19. Pelton, K. et al. (2012) Cholesterol and prostate cancer. Curr. Opin. Pharmacol. 12, 751-578 
759 579 
20. Chen, M. et al. (2018) An aberrant SREBP-dependent lipogenic program promotes 580 
metastatic prostate cancer. Nat. Genet. 50, 206-218 581 
21. Griffiths, B. et al. (2013) Sterol regulatory element binding protein-dependent regulation of 582 
lipid synthesis supports cell survival and tumor growth. Cancer Metab 1, 3 583 
22. Yue, S. et al. (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT 584 
activation underlies human prostate cancer aggressiveness. Cell Metab 19, 393-406 585 
23. John, S. et al. (2017) Extracellular Proton Concentrations Impacts LN229 Glioblastoma 586 
Tumor Cell Fate via Differential Modulation of Surface Lipids. Front Oncol. 7, 20 587 
24. Zhuang, L. et al. (2005) Cholesterol targeting alters lipid raft composition and cell survival 588 
in prostate cancer cells and xenografts. J. Clin. Invest. 115, 959-968 589 
25. Ushio-Fukai, M. et al. (2001) Cholesterol Depletion Inhibits Epidermal Growth Factor 590 
Receptor Transactivation by Angiotensin II in Vascular Smooth Muscle Cells. Role of 591 
cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J. Biol. Chem. 592 
276, 48269-48275 593 
26. Simons, K. and Ehehalt, R. (2002) Cholesterol, lipid rafts, and disease. J. Clin. Invest. 594 
110, 597-603 595 
27. Wang, X. et al. (2015) Aromatase overexpression in dysfunctional adipose tissue links 596 
obesity to postmenopausal breast cancer. J. Steroid Biochem. Mol. Biol. 153, 35-44 597 
28. Mitsiades, N. et al. (2012) Distinct patterns of dysregulated expression of enzymes 598 
involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer 599 
Res. 72, 6142-6152 600 
29. Goss, P.E. et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N. 601 
Engl. J. Med. 375, 209-219 602 
30. Clinton, G.M. and Hua, W. (1997) Estrogen action in human ovarian cancer. Crit Rev. 603 
Oncol. Hematol. 25, 1-9 604 
23 
 
31. Imachi, H. et al. (1999) Evidence for a potential role for HDL as an important source of 605 
cholesterol in human adrenocortical tumors via the CLA-1 pathway. Endocr. J. 46, 27-34 606 
32. Nelson, E.R. et al. (2014) Cholesterol and breast cancer pathophysiology. Trends 607 
Endocrinol. Metab 25, 649-655 608 
33. York, A.G. and Bensinger, S.J. (2013) Subverting sterols: rerouting an oxysterol-signaling 609 
pathway to promote tumor growth. J. Exp. Med. 210, 1653-1656 610 
34. Wang, Q. et al. (2014) Identification of interferon-gamma as a new molecular target of 611 
liver X receptor. Biochem. J. 459, 345-354 612 
35. Lee, J.H. et al. (2008) Androgen deprivation by activating the liver X receptor. 613 
Endocrinology 149, 3778-3788 614 
36. Leignadier, J. et al. (2017) Improving the efficacy of hormone therapy in breast cancer: 615 
The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and 616 
death. Biochem. Pharmacol. 144, 18-28 617 
37. Alfaqih, M.A. et al. (2017) CYP27A1 Loss Dysregulates Cholesterol Homeostasis in 618 
Prostate Cancer. Cancer Res. 77, 1662-1673 619 
38. Raza, S. et al. (2017) The cholesterol metabolite 27-hydroxycholesterol stimulates cell 620 
proliferation via ERbeta in prostate cancer cells. Cancer Cell Int. 17, 52 621 
39. Wang, D. and Dubois, R.N. (2010) Eicosanoids and cancer. Nat. Rev. Cancer 10, 181-622 
193 623 
40. Tong, D. et al. (2018) The roles of the COX2/PGE2/EP axis in therapeutic resistance. 624 
Cancer Metastasis Rev. 37, 355-368 625 
41. Reinartz, S. et al. (2016) A transcriptome-based global map of signaling pathways in the 626 
ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 17, 108 627 
42. Nie, D. et al. (2008) Thromboxane A2 receptors in prostate carcinoma: expression and its 628 
role in regulating cell motility via small GTPase Rho. Cancer Res. 68, 115-121 629 
43. Zhang, Q. et al. (2017) Resolution of Cancer-Promoting Inflammation: A New Approach 630 
for Anticancer Therapy. Front Immunol. 8, 71 631 
44. Sulciner, M.L. et al. (2018) Targeting lipid mediators in cancer biology. Cancer Metastasis 632 
Rev. 37, 557-572 633 
45. Wang, M. and Casey,P.J. (2016) Protein prenylation: unique fats make their mark on 634 
biology. Nat. Rev. Mol. Cell Biol. 17, 110-122 635 
46. Karp, J.E. and Lancet, J.E. (2007) Development of farnesyltransferase inhibitors for 636 
clinical cancer therapy: focus on hematologic malignancies. Cancer Invest 25, 484-494 637 
24 
 
47. Resh, M.D. (2012) Targeting protein lipidation in disease. Trends Mol. Med. 18, 206-214 638 
48. Lanyon-Hogg, T. et al. (2017) Dynamic Protein Acylation: New Substrates, Mechanisms, 639 
and Drug Targets. Trends Biochem. Sci. 42, 566-581 640 
49. Danilo, C. and Frank, P.G. (2012) Cholesterol and breast cancer development. Curr. 641 
Opin. Pharmacol. 12, 677-682 642 
50. De Boussac, H. et al. (2013) LXR, prostate cancer and cholesterol: the Good, the Bad 643 
and the Ugly. Am. J. Cancer Res. 3, 58-69 644 
51. Jamnagerwalla, J. et al. (2018) Serum cholesterol and risk of high-grade prostate cancer: 645 
results from the REDUCE study. Prostate Cancer Prostatic. Dis. 21, 252-259 646 
52. Allott, E.H. et al. (2017) Statin Use, Serum Lipids, and Prostate Inflammation in Men with 647 
a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prev. Res. (Phila) 10, 648 
319-326 649 
53. Mondul, A.M. et al. (2011) Serum total and HDL cholesterol and risk of prostate cancer. 650 
Cancer Causes Control 22, 1545-1552 651 
54. YuPeng, L. et al. (2015) Cholesterol Levels in Blood and the Risk of Prostate Cancer: A 652 
Meta-analysis of 14 Prospective Studies. Cancer Epidemiol. Biomarkers Prev. 24, 1086-1093 653 
55. Touvier, M. et al. (2015) Cholesterol and breast cancer risk: a systematic review and 654 
meta-analysis of prospective studies. Br. J. Nutr. 114, 347-357 655 
56. Sadeghi, A. et al. (2019) Dietary Fat Intake and Risk of Ovarian Cancer: A Systematic 656 
Review and Dose-Response Meta-Analysis of Observational Studies. Nutr. Cancer 71, 939-657 
953 658 
57. Bull, C.J. et al. (2016) Blood lipids and prostate cancer: a Mendelian randomization 659 
analysis. Cancer Med. 5, 1125-1136 660 
58. Nowak, C. and Arnlov, J. (2018) A Mendelian randomization study of the effects of blood 661 
lipids on breast cancer risk. Nat. Commun. 9, 3957 662 
59. Yamashita, S. and Matsuzawa, Y. (2016) Re-evaluation of cholesteryl ester transfer 663 
protein function in atherosclerosis based upon genetics and pharmacological manipulation. 664 
Curr. Opin. Lipidol. 27, 459-472 665 
60. Li, C. et al. (2016) Systematic review and meta-analysis suggest that dietary cholesterol 666 
intake increases risk of breast cancer. Nutr. Res. 36, 627-635 667 
61. Tan, P. et al. (2016) The effect of statins on prostate cancer recurrence and mortality after 668 
definitive therapy: a systematic review and meta-analysis. Sci. Rep. 6, 29106 669 
62. Undela, K. et al. (2012) Statin use and risk of breast cancer: a meta-analysis of 670 
observational studies. Breast Cancer Res. Treat. 135, 261-269 671 
25 
 
63. Emberson, J.R. et al. (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-672 
analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. 673 
PLoS. ONE. 7, e29849 674 
64. Ganjali, S. et al. (2019) High-Density Lipoprotein Components and Functionality in 675 
Cancer: State-of-the-Art. Trends Endocrinol. Metab 30, 12-24 676 
65. Michalaki, V. et al. (2005) Evaluation of serum lipids and high-density lipoprotein 677 
subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol. Cell 678 
Biochem. 268, 19-24 679 
66. Kozak, K.R. et al. (2003) Identification of biomarkers for ovarian cancer using strong 680 
anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. 681 
U. S. A. 100, 12343-12348 682 
67. Pirro, M. et al. (2018) High density lipoprotein cholesterol and cancer: Marker or 683 
causative? Prog. Lipid Res. 71, 54-69 684 
68. Mansourian, M. et al. (2016) Statins Use and Risk of Breast Cancer Recurrence and 685 
Death: A Systematic Review and Meta-Analysis of Observational Studies. J. Pharm. Pharm. 686 
Sci. 19, 72-81 687 
69. Borgquist, S. et al. (2017) Cholesterol, Cholesterol-Lowering Medication Use, and Breast 688 
Cancer Outcome in the BIG 1-98 Study. J. Clin. Oncol. 35, 1179-1188 689 
70. Zhou, P. et al. (2018) Prognostic role of serum total cholesterol and high-density 690 
lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis. Clin. 691 
Chim. Acta 477, 94-104 692 
71. Alikhani, N. et al. (2013) Mammary tumor growth and pulmonary metastasis are enhanced 693 
in a hyperlipidemic mouse model. Oncogene 32, 961-967 694 
72. Gallagher, E.J. et al. (2017) Elevated tumor LDLR expression accelerates LDL 695 
cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia. Oncogene 36, 696 
6462-6471 697 
73. Antalis, C.J. et al. (2010) High ACAT1 expression in estrogen receptor negative basal-like 698 
breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res. Treat. 699 
122, 661-670 700 
74. Llaverias, G. et al. (2010) A Western-type diet accelerates tumor progression in an 701 
autochthonous mouse model of prostate cancer. Am. J. Pathol. 177, 3180-3191 702 
75. Wolfe, A.R. et al. (2015) High-density and very-low-density lipoprotein have opposing 703 
roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast 704 
cancer. Int. J. Radiat. Oncol. Biol. Phys. 91, 1072-1080 705 
76. Scoles, D.R. et al. (2010) Liver X receptor agonist inhibits proliferation of ovarian 706 
carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol. Oncol. 116, 109-116 707 
26 
 
77. Gonzalez-Chavarria, I. et al. (2018) LOX-1 activation by oxLDL triggers an epithelial 708 
mesenchymal transition and promotes tumorigenic potential in prostate cancer cells. Cancer 709 
Lett. 414, 34-43 710 
78. Balzan, S. and Lubrano, V. (2018) LOX-1 receptor: A potential link in atherosclerosis and 711 
cancer. Life Sci. 198, 79-86 712 
79. Kuemmerle, N.B. et al. (2011) Lipoprotein lipase links dietary fat to solid tumor cell 713 
proliferation. Mol. Cancer Ther. 10, 427-436 714 
80. Balaban, S. et al. (2017) Adipocyte lipolysis links obesity to breast cancer growth: 715 
adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer 716 
Metab 5, 1 717 
81. Nieman, K.M. et al. (2013) Adipose tissue and adipocytes support tumorigenesis and 718 
metastasis. Biochim. Biophys. Acta 1831, 1533-1541 719 
82. Caro-Maldonado, A. et al. (2018) Low-dose statin treatment increases prostate cancer 720 
aggressiveness. Oncotarget. 9, 1494-1504 721 
83. Guillaumond, F. et al. (2015) Cholesterol uptake disruption, in association with 722 
chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. 723 
Proc. Natl. Acad. Sci. U. S. A. 112, 2473-2478 724 
84. Lee, H.J. et al. (2018) Cholesterol Esterification Inhibition Suppresses Prostate Cancer 725 
Metastasis by Impairing the Wnt/beta-catenin Pathway. Mol. Cancer Res. 16, 974-985 726 
85. LaPensee, C.R. et al. (2016) ATR-101, a Selective and Potent Inhibitor of Acyl-CoA 727 
Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal 728 
Cortex of Dogs. Endocrinology 157, 1775-1788 729 
86. Li, J. et al. (2016) Abrogating cholesterol esterification suppresses growth and metastasis 730 
of pancreatic cancer. Oncogene 35, 6378-6388 731 
87. Lippi, G. et al. (2007) Lipoprotein[a] and cancer: anti-neoplastic effect besides its 732 
cardiovascular potency. Cancer Treat. Rev. 33, 427-436 733 
88. Zamanian-Daryoush, M. and DiDonato, J.A. (2015) Apolipoprotein A-I and Cancer. Front 734 
Pharmacol. 6, 265 735 
89. Miura, S. et al. (1997) Cholesterol-mediated changes of neutral cholesterol esterase 736 
activity in macrophages. Mechanism for mobilization of cholesteryl esters in lipid droplets by 737 
HDL. Arterioscler. Thromb. Vasc. Biol. 17, 3033-3040 738 
90. Ruscica, M. et al. (2018) High Density Lipoproteins Inhibit Oxidative Stress-Induced 739 
Prostate Cancer Cell Proliferation. Sci. Rep. 8, 2236 740 
27 
 
91. Danilo, C. et al. (2013) Scavenger receptor class B type I regulates cellular cholesterol 741 
metabolism and cell signaling associated with breast cancer development. Breast Cancer 742 
Res. 15, R87 743 
92. Cao, W.M. et al. (2004) A mutant high-density lipoprotein receptor inhibits proliferation of 744 
human breast cancer cells. Cancer Res. 64, 1515-1521 745 
93. Ossoli, A. et al. (2019) Dysfunctional HDL as a Therapeutic Target for Atherosclerosis 746 
Prevention. Curr. Med. Chem. 26, 1610-1630 747 
94. Pan, B. et al. (2012) High-density lipoprotein of patients with type 2 diabetes mellitus 748 
elevates the capability of promoting migration and invasion of breast cancer cells. Int. J. 749 
Cancer 131, 70-82 750 
95. Huang, X. et al. (2016) High-density lipoprotein of patients with breast cancer complicated 751 
with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via 752 
ICAM-1 and VCAM-1 upregulation. Breast Cancer Res. Treat. 155, 441-455 753 
96. Krause, B.R. and Remaley, A.T. (2013) Reconstituted HDL for the acute treatment of 754 
acute coronary syndrome. Curr. Opin. Lipidol. 24, 480-486 755 
97. Morin, E.E. et al. (2018) HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and 756 
Potential Therapeutic. Front Endocrinol. (Lausanne) 9, 715 757 
98. Foit, L. et al. (2015) Synthetic high-density lipoprotein-like nanoparticles for cancer 758 
therapy. Expert. Rev. Anticancer Ther. 15, 27-34 759 
99. Tang, J. et al. (2017) Effect of size and pegylation of liposomes and peptide-based 760 
synthetic lipoproteins on tumor targeting. Nanomedicine. 13, 1869-1878 761 
100. Mooberry, L.K. et al. (2010) Receptor mediated uptake of paclitaxel from a synthetic high 762 
density lipoprotein nanocarrier. J. Drug Target 18, 53-58 763 
101. Zhang, F. et al. (2016) Reconstituted high density lipoprotein mediated targeted co-764 
delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-765 
7 breast cancer cells. Eur. J. Pharm. Sci. 92, 11-21 766 
102. Sabnis, N. et al. (2012) Enhanced solubility and functionality of valrubicin (AD-32) 767 
against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. 768 
Nanomedicine. 7, 975-983 769 
103. Bray, F. et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence 770 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394-424 771 
104. Goldhirsch, A. et al. (2011) Strategies for subtypes--dealing with the diversity of breast 772 
cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of 773 
Early Breast Cancer 2011. Ann. Oncol. 22, 1736-1747 774 
28 
 
105. Epstein, J.I. et al. (2016) The 2014 International Society of Urological Pathology (ISUP) 775 
Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading 776 
Patterns and Proposal for a New Grading System. Am. J. Surg. Pathol. 40, 244-252 777 
106. Weinberg, S.E. and Chandel, N.S. (2015) Targeting mitochondria metabolism for cancer 778 
therapy. Nat. Chem. Biol. 11, 9-15 779 
107. Fischer, K. et al. (2007) Inhibitory effect of tumor cell-derived lactic acid on human T 780 
cells. Blood 109, 3812-3819 781 
108. Liu, Y. et al. (2010) Dominant uptake of fatty acid over glucose by prostate cells: a 782 
potential new diagnostic and therapeutic approach. Anticancer Res. 30, 369-374 783 
109. Kim, W.Y. (2019) Therapeutic targeting of lipid synthesis metabolism for selective 784 
elimination of cancer stem cells. Arch. Pharm. Res. 42, 25-39 785 
110. Havel, R.J. and Kane, J.P. (2001) Structure and metabolism of plasma lipoproteins. In 786 
The Metabolic and Molecular Basis of Inherited Diseases (Scriver,C.R., ed), McGraw-Hill 787 
111. Borrelli, M.J. et al. (2019) New Frontiers in Lp(a)-Targeted Therapies. Trends 788 
Pharmacol. Sci. 40, 212-225 789 
112. Calabresi, L. et al. (2006) Synthetic high density lipoproteins for the treatment of 790 
myocardial ischemia/reperfusion injury. Pharmacol. Ther. 111, 836-854 791 
113. Mundi, S. et al. (2018) Endothelial permeability, LDL deposition, and cardiovascular risk 792 
factors-a review. Cardiovasc. Res. 114, 35-52 793 
114. Horton, J.D. et al. (2002) SREBPs: activators of the complete program of cholesterol and 794 
fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 795 
115. Wang, B. and Tontonoz, P. (2018) Liver X receptors in lipid signalling and membrane 796 
homeostasis. Nat. Rev. Endocrinol. 14, 452-463 797 
116. Venkateswaran, A. et al. (2000) Control of cellular cholesterol efflux by the nuclear 798 
oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U. S. A. 97, 12097-12102 799 
117. Zelcer, N. et al. (2009) LXR regulates cholesterol uptake through Idol-dependent 800 
ubiquitination of the LDL receptor. Science 325, 100-104 801 
118. Febbraio, M. et al. (2001) CD36: a class B scavenger receptor involved in angiogenesis, 802 
atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785-791 803 
119. Gomaraschi, M. et al. (2006) High-density lipoproteins: a therapeutic target for 804 
atherosclerotic cardiovascular disease. Expert. Opin. Ther. Targets. 10, 561-572 805 
120. Vickers, K.C. et al. (2011) MicroRNAs are transported in plasma and delivered to 806 
recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423-433 807 
 808 
Outstanding questions 
 
The modulation of plasma levels of lipids by genetic manipulation and/or dietary approaches 
affected tumor development in mice. However, epidemiological and interventional studies in 
humans gave inconsistent results. What is the relevance of circulating versus local lipids for 
tumor development and progression? 
 
The inhibition of cholesterol synthesis and lipoprotein uptake in cancer cells can affect cell 
viability. To this aim, statins are not promising due to their distribution and mechanism of 
action. The development of LXR agonists is hampered by their side effects. Other 
approaches, as the inhibition of the SREBP pathway or the silencing of the LDL-R are under 
investigation. In addition, the role of lipoprotein remnants in cancer biology has not been 
addressed to date. What is the optimal target for reducing cholesterol content in cancer cells? 
 
The HDL system seems a promising target to limit cancer cell content of cholesterol and its 
metabolites. The development of HDL-targeted approaches should consider the role of SR-BI, 
which could be upregulated in cancer and promote cholesterol uptake from HDL. Could small 
discoidal reconstituted HDL overcome this problem? 
 
Lipid metabolites as oxysterols and eicosanoids are produced in the TME and can affect both 
cancer and stromal cells; these metabolites need further dedicated investigations since 
different molecules seem to exert opposite effects on cancer cells. Is the pattern of oxysterol 
and eicosanoid production in cancer cell modifiable? 
 
Plasma levels of apoA-I are used as a biomarker for ovarian cancer. Acute reduction of 
circulating HDL-C along with apoA-I is common during active disease in many cancer types. 
Could plasma levels of apoA-I be used as a biomarker for other types of tumor? 
Outstanding Questions
Trends 
 
Tumor microenvironment (TME) can favor tumor progression and TME signature can predict 
disease outcome. Sources of lipids, pro-inflammatory and pro-oxidant molecules are present 
in the TME, including lipoproteins. 
 
Cholesterol affects cell proliferation as a component of lipid rafts regulating cell signaling, and 
as building block for the local synthesis of hormones and oxysterols. 
 
Very low- and low-density lipoproteins in the TME can provide cancer cells with lipids and 
exert pro-inflammatory and pro-oxidant activities. 
 
High density lipoproteins (HDL) can promote the removal of cholesterol and its metabolites 
from cancer cell and blunt inflammation and oxidative stress. Boosting the HDL system by the 
infusion of reconstituted HDL could represent a promising approach to affect cancer cell 
viability. 
Highlights
